
Panagiotis A Konstantinopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2889245/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature, 2016, 535, 382-387.	27.8	685
2	Homologous-recombination-deficient tumours are dependent on PolÎ,-mediated repair. Nature, 2015, 518, 258-262.	27.8	671
3	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discovery, 2015, 5, 1137-1154.	9.4	657
4	Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncology, 2015, 1, 1319.	7.1	523
5	DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discovery, 2017, 7, 675-693.	9.4	519
6	Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget, 2016, 7, 13587-13598.	1.8	485
7	Gene Expression Profile of <i>BRCA</i> ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer. Journal of Clinical Oncology, 2010, 28, 3555-3561.	1.6	465
8	PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Reports, 2018, 25, 2972-2980.e5.	6.4	381
9	Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncology, 2019, 5, 1141.	7.1	355
10	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discovery, 2018, 8, 1404-1421.	9.4	311
11	A single-cell landscape of high-grade serous ovarian cancer. Nature Medicine, 2020, 26, 1271-1279.	30.7	267
12	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nature Cell Biology, 2017, 19, 1371-1378.	10.3	257
13	Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer. Cancer Research, 2011, 71, 5081-5089.	0.9	243
14	Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1222-1245.	1.6	202
15	Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	10.7	191
16	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature Communications, 2020, 11, 1459.	12.8	176
17	DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature, 2018, 563, 522-526.	27.8	156
18	Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. JAMA Oncology, 2019, 5, 1731.	7.1	150

PANAGIOTIS A

#	Article	IF	CITATIONS
19	Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 957-968.	10.7	140
20	PARP inhibitors in ovarian cancer: Current status and future promise. Gynecologic Oncology, 2014, 133, 362-369.	1.4	126
21	Resistance to therapy in <i>BRCA2</i> mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes and Development, 2015, 29, 489-494.	5.9	124
22	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Reports, 2016, 14, 429-439.	6.4	118
23	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clinical Cancer Research, 2016, 22, 5651-5660.	7.0	116
24	Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. ELife, 2018, 7, .	6.0	109
25	Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. ELife, 2017, 6, .	6.0	106
26	A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance. Cancer Research, 2015, 75, 628-634.	0.9	104
27	The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clinical Cancer Research, 2019, 25, 6127-6140.	7.0	104
28	Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecologic Oncology, 2014, 133, 599-606.	1.4	103
29	TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort Journal of Clinical Oncology, 2018, 36, 106-106.	1.6	101
30	Gene-expression profiling in epithelial ovarian cancer. Nature Clinical Practice Oncology, 2008, 5, 577-587.	4.3	92
31	Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. Journal of Clinical Oncology, 2021, 39, 1531-1539.	1.6	88
32	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncolmmunology, 2017, 6, e1277308.	4.6	84
33	Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecologic Oncology, 2020, 159, 887-898.	1.4	70
34	Evolutionarily conserved serum microRNAs predict radiation-induced fatality in nonhuman primates. Science Translational Medicine, 2017, 9, .	12.4	69
35	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications, 2022, 13, .	12.8	68
36	MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. ELife, 2014, 3, e02445.	6.0	64

#	Article	IF	CITATIONS
37	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Reports, 2018, 23, 100-111.	6.4	60
38	Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer. Trends in Cancer, 2019, 5, 524-528.	7.4	57
39	Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecologic Oncology, 2020, 156, 488-497.	1.4	51
40	Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget, 2014, 5, 2678-2687.	1.8	47
41	Carboplatin-induced gene expression changes in vitroare prognostic of survival in epithelial ovarian cancer. BMC Medical Genomics, 2008, 1, 59.	1.5	46
42	Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-CY001). Gynecologic Oncology, 2018, 150, 9-13.	1.4	44
43	Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecologic Oncology, 2020, 159, 72-78.	1.4	41
44	An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecologic Oncology, 2014, 134, 331-337.	1.4	40
45	Homologous recombination deficiency real-time clinical assays, ready or not?. Gynecologic Oncology, 2020, 159, 877-886.	1.4	39
46	Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer. Cell Cycle, 2014, 13, 199-207.	2.6	36
47	Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer. PLoS ONE, 2011, 6, e18202.	2.5	35
48	Seeing the Future of Cancer-Associated Transcription Factor Drug Targets. JAMA - Journal of the American Medical Association, 2011, 305, 2349.	7.4	34
49	Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer. Frontiers in Oncology, 2013, 3, 296.	2.8	34
50	From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation. British Journal of Cancer, 2018, 118, 933-935.	6.4	34
51	PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094411.	3.2	34
52	Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Modern Pathology, 2016, 29, 893-903.	5.5	33
53	A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nature Communications, 2021, 12, 5574.	12.8	32
54	Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. Nature Communications, 2022, 13, 835.	12.8	32

#	Article	IF	CITATIONS
55	PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey. Clinical Cancer Research, 2018, 24, 4062-4065.	7.0	31
56	Phase II, 2â€stage, 2â€erm, PIK3CA mutation stratified trial of MKâ€2206 in recurrent endometrial cancer. International Journal of Cancer, 2020, 147, 413-422.	5.1	31
57	PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e116-e131.	3.8	30
58	Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecologic Oncology, 2019, 154, 95-101.	1.4	29
59	Prognostic implications of reproductive and lifestyle factors in ovarian cancer. Gynecologic Oncology, 2016, 142, 574-587.	1.4	27
60	Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecologic Oncology Reports, 2017, 19, 42-45.	0.6	24
61	Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. , 2022, 10, e004233.		24
62	Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC) Journal of Clinical Oncology, 2013, 31, 5524-5524.	1.6	22
63	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 1493-1499.	7.0	22
64	Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 997-1010.	2.2	20
65	Morphologic and immunophenotypic evidence of in-situ Kaposi's sarcoma. BMC Clinical Pathology, 2006, 6, 7.	1.8	18
66	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecologic Oncology, 2019, 153, 471-478.	1.4	18
67	Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. British Journal of Cancer, 2022, 126, 1027-1036.	6.4	18
68	<scp><i>POLE</i></scp> mutations as an alternative pathway for microsatellite instability in endometrial cancer: Implications for <scp>L</scp> ynch syndrome testing. Cancer, 2015, 121, 331-334.	4.1	17
69	Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. Gynecologic Oncology, 2018, 150, 219-226.	1.4	17
70	Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecologic Oncology Reports, 2019, 29, 118-122.	0.6	17
71	Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?. Journal of Clinical Oncology, 2021, 39, 1833-1838.	1.6	17
72	17-AAG: mechanisms of antitumour activity. Expert Opinion on Investigational Drugs, 2005, 14, 1471-1474.	4.1	14

#	Article	IF	CITATIONS
73	Analysis of Multiple Sarcoma Expression Datasets: Implications for Classification, Oncogenic Pathway Activation and Chemotherapy Resistance. PLoS ONE, 2010, 5, e9747.	2.5	14
74	Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. Oncoscience, 2015, 2, 942-943.	2.2	14
75	Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clinical Cancer Research, 2022, 28, 3356-3366.	7.0	13
76	Management of Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1420.	7.4	12
77	Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. JCO Precision Oncology, 2020, 4, 736-742.	3.0	12
78	Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms. American Journal of Surgical Pathology, 2022, 46, 169-178.	3.7	12
79	HIV-Associated Anal Squamous Cell Cancer: An Otherwise Preventable Disease. Journal of Clinical Oncology, 2006, 24, 4516-4517.	1.6	11
80	Investigational agents for treatment of AIDS-related Kaposi's sarcoma. Expert Opinion on Investigational Drugs, 2007, 16, 495-504.	4.1	11
81	Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Modern Pathology, 2021, 34, 613-626.	5.5	11
82	Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma. JCO Precision Oncology, 2018, 2018, 1-8.	3.0	8
83	POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure. Gynecologic Oncology Reports, 2019, 28, 15-17.	0.6	8
84	Identification and Management of Pathogenic Variants in <i>BRCA1</i> , <i>BRCA2</i> , and <i>PALB2</i> in a Tumor-Only Genomic Testing Program. Clinical Cancer Research, 2022, 28, 2349-2360.	7.0	8
85	Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies. Expert Opinion on Investigational Drugs, 2021, 30, 695-707.	4.1	7
86	Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers Journal of Clinical Oncology, 2015, 33, 5512-5512.	1.6	7
87	MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC) Journal of Clinical Oncology, 2022, 40, 5573-5573.	1.6	7
88	Acquired immunodeficiency syndrome related Kaposi's sarcoma eroding the maxillary bone. Journal of Laryngology and Otology, 2008, 122, 993-997.	0.8	6
89	Genomic testing and precision medicine — What does this mean for gynecologic oncology?. Gynecologic Oncology, 2016, 140, 3-5.	1.4	5
90	Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib. Journal of Cancer Research and Clinical Oncology, 2020, 146, 503-514.	2.5	5

#	Article	IF	CITATIONS
91	Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecologic Oncology, 2021, 161, 581-586.	1.4	5
92	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecologic Oncology Reports, 2022, 40, 100974.	0.6	5
93	HIV-Associated Intramammary Lymphadenopathy. Breast Journal, 2007, 13, 192-195.	1.0	4
94	BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab—Reply. JAMA Oncology, 2020, 6, 441.	7.1	4
95	MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma. Gynecologic Oncology, 2021, 163, 453-458.	1.4	3
96	ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer Journal of Clinical Oncology, 2022, 40, TPS5609-TPS5609.	1.6	3
97	Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers—Reply. JAMA Oncology, 2016, 2, 141.	7.1	1
98	Abstract 2747: Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. , 2021, , .		0
99	Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival Journal of Clinical Oncology, 2012, 30, 8528-8528.	1.6	0
100	Images in HIV/AIDS. HIV-associated squamous cell carcinoma of the anus. Aids Reader, 2006, 16, 301-2.	0.3	0
101	Uterine carcinosarcoma associated with a germline nibrin (NBN) mutation. Gynecologic Oncology Reports, 2022, 40, 100979.	0.6	Ο